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httpcense.Abstract Background: Chronic obstructive pulmonary disease (COPD) is a major factor for dis-
ease related loss of quality of life, health expenditure and loss of productivity. An enhanced and
persistent inﬂammatory response to the inhalation of particles and gases, mostly tobacco smoking,
is considered a key pathogenic mechanism of COPD. Recent evidence indicates that autoimmunity
plays a signiﬁcant role in this response.
Aim of the work: This study investigated the role of autoimmunity in the pathogenesis of COPD
by determining the prevalence of circulating autoantibodies in these patients and in healthy controls
and evaluating their relationship with several disease components.
Patient and methods: This study included 31 COPD patients and 12 healthy non-smoker con-
trols. All individuals were subjected to detailed history taking, full clinical examination, BMI cal-
culation, arterial blood gas analysis, spirometry, 6MWD and assessment of serum level of
circulating autoantibodies.ve pulmonary disease; BMI, body mass index; 6MWD, 6 min walk distance; ABG, arterial blood gases;
; PaCO2, partial pressure of arterial carbon dioxide; SaO2, oxyhemoglobin saturation; CD4+, cluster of
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mmunoﬂuorescence; SD, standard deviation; P-value, probability value; SPSS, statistical package for the
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356 M.M. Shaban et al.Results: There was a statistically signiﬁcant difference between COPD patients and healthy con-
trols in the spirometric data, PaO2, SO2 and 6MWD; however there was no statistically signiﬁcant
difference between both groups in the prevalence of autoantibodies. Also there was no statistically
signiﬁcant correlation between the prevalence of autoantibodies and other variables such as age,
BMI, 6MWD, spirometric and ABG parameters.
Conclusion: The prevalence of positive circulating autoantibodies in COPD patients was found
not signiﬁcant when compared with healthy non smoker control group. This ﬁnding does not sup-
port a role for autoimmunity in the pathogenesis of COPD. So the hypothesis that autoimmunity
plays a role in the pathogenesis in COPD needs further exploration.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD) is a common
preventable and treatable disease, characterized by persistent
airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the air-
ways and the lung to noxious particles or gases. Exacerbations
and comorbidities contribute to the overall severity in individ-
ual patients [1].
It is now increasingly recognized that (COPD)/emphysema
presents clinically as a syndrome with pulmonary and extra-
pulmonary manifestations [2]. Interestingly, only 15–20% of
smokers develop COPD, suggesting that genetic predisposition
and environmental factors play a role in the pathogenesis of
the disease [3].
It has been hypothesized that there may be an autoimmune
component to the chronic progressive lung tissue destruction
which can persist after smoking cessation [4,5].
There is some evidence to support the contention that there
is increased acquired immunity in COPD: (1) both helper
(CD4+) and cytotoxic T lymphocytes (CD8+) accumulate
in the lung parenchyma of patients with COPD [6]; (2) B lym-
phocytes form the core of the so-called bronchus-associated
lymphoid tissue (BALT) which has been shown to be signiﬁ-
cantly increased in smokers and in patients with COPD [7,8];
(3) smoking is associated with an expansion of the population
of antigen presenting cells on the epithelial surface of the lower
respiratory tract [9].
The aim of the present study was to explore the role of
autoimmunity in the pathogenesis of COPD by determining
the prevalence of circulating autoantibodies in patients with
COPD and healthy controls and evaluating their relationship
with age, body mass index, spirometric parameters and arterial
blood gases.
Subjects
The present study included thirty one male patients who
fulﬁlled the criteria for COPD according to the American Tho-
racic Society/European Respiratory Society recommendations
[10]. All patients were P50 years of age and P10 pack-year
history of cigarette smoking. They were stable at the time of
the examination with no other comorbid conditions or autoim-
mune diseases. Also patients younger than 45 years of age and
patients with other pulmonary lesions e.g.; cancer, residual
extensive tuberculous lesion or pulmonary ﬁbrosis were
excluded.The control group included twelve healthy male controls
with no smoking history.
Methods
All included individuals were subjected to: detailed history
taking, full clinical examination, plain chest X-ray (P–A view)
to exclude other chest problems. Body mass index, ﬂow/
volume loop using body plethysmography with highly trans-
parent box; Sensor-medics V max series, 2130 Spirometer,
V6200Autobox, 6200DL, arterial blood gases to estimate
PaCO2, PaO2 and SO2 using a blood gas analyzer (PHOX
PLUS C), six min walk test and serum level of circulating
autoantibodies.
Body mass index (BMI), or quetelet index
It is deﬁned as the individual’s body weight divided by the
square of their height with the value universally being given
in units of kg/m2 [11].
Pulmonary function test
(Flow/volume loop): spirometry indices are reported compar-
ing the individual’s value along with the predicted values.
The forced vital capacity (FVC), the forced expiratory volume
in the ﬁrst second (FEV1), the ratio of FEV1 to FVC and the
forced expiratory ﬂow at 25–75% of FVC (FEF25–75%) were
measured. The presence of a post bronchodilator FEV1/FVC
ratio <0.70 conﬁrms the presence of airﬂow limitation. Bron-
chodilator challenge test was performed to conﬁrm that the air
ﬂow limitation is not fully reversible. Reversible airway
obstruction is considered signiﬁcant when there is an increase
in the pre-bronchodilator FEV1 by both greater than 200 ml
(absolute change) and 12% (% change) [12].
Arterial blood gases
One ml of arterial blood was obtained from the radial artery in
a heparinized syringe, once the sample is obtained, care is
taken to eliminate visible gas bubbles, as these bubbles can
dissolve into the sample and cause inaccurate results. The
sealed syringe is taken immediately to a blood gas analyzer
(PHOX PLUS C) which aspirates this blood from the syringe
and measures the partial pressures of arterial oxygen, carbon
dioxide and oxygen saturation [13].
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Figure 1 Statistical comparison between COPD cases and
control group in mean value of age and BMI.
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Figure 2 Statistical comparison between COPD cases and
control group in the spirometric data.
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It was conducted in a 30 m long, ﬂat corridor. Standardized
instructions and encouragement were given, according to ATS
guidelines [14]. Patients were instructed to walk as far and as
fast as possible during the time that is. They were told that they
could slow down or even stop if necessary. Standard phrases of
encouragement at regular intervals (every 60 s) were used aim-
ing to increase the distance walked. The test was discontinued
if the patient had chest pain, intolerable dyspnea, cramps, dizzi-
ness, staggering, diaphoresis, pallor or SO2 <90% [14].
Assessment of serum level of circulating autoantibodies
Venous blood sample (10 ml) was obtained by peripheral veni-
puncture in the early morning after fasting overnight. Active
smokers were asked to refrain from smoking before 8 h. Blood
was centrifuged at 2000 rpm for 10 min immediately after
sampling and serum was stored frozen at 80 C until analysis.
Circulating autoantibodies: the serum titers of antinuclear
antibodies (ANA) were quantiﬁed by indirect immunoﬂuores-
cence on Hep2 lines (INOVA, San Diego, USA). In ANA po-
sitive samples with a homogeneous pattern, we tested the
presence of anti-double stranded DNA (dsDNA) antibodies
by IFI on Crithidia luciliae slides. Anti-tissue autoantibodies
(AT) including mitochondrial (AMA), smooth muscle (SMA)
and parietal gastric cell (PGC) autoantibodies were determined
by immunoﬂuorescence on composite block of rodent liver,
kidney and stomach sections (Inmunoﬂuor ANA-AMA-
SMA-APCA, MT, Promedt Consulting GmbH, St. Ingbert,
Germany). All tests were blindly performed by a technician
and reviewed by an immunologist. Both for ANA and AT, ti-
ters <1:80 were considered negative whereas those 1:160,
1:320 and >1:320 were considered increasingly positive [15].
Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), median and range or frequencies (number of
cases) and percentages when appropriate. Comparison of
numerical variables between the study groups was done using
Student’s t test for independent samples. For comparing cate-
gorical data, Chi square (v2) test was performed. Exact test was
used instead when the expected frequency is less than 5. Corre-
lation between various variables was done using Spearman
rank correlation equation. p-Values less than 0.05 was consid-
ered statistically signiﬁcant. All statistical calculations were
done using computer programs SPSS (Statistical Package for
the Social Science; SPSS Inc., Chicago, IL, USA) version 15
for Microsoft Windows.
Results
In the present study, there was no statistically signiﬁcant dif-
ference between COPD cases and healthy control group in
the mean age and mean value of BMI as shown in Fig. 1, how-
ever there was a statistically signiﬁcant difference between both
groups in the spirometric data (Fig. 2), arterial blood gases
parameters (Table 1) and 6MWD (Fig. 3).
By comparing COPD patients and healthy control groups
in the level of serum circulating autoantibodies, it was foundthat there was no statistically signiﬁcant difference in the level
of ANA, ASMA, AMA and APA between both groups (Ta-
ble 2 and Fig. 4). The presence of Anti-double stranded
DNA antibodies was tested only in the two COPD patients
with positive homogenous ANA to exclude SLE and it was
negative in these patients. Also the comparison between
COPD cases and healthy control group was done according
to the grade of positivity of ASMA because it may occur in
normal healthy individuals but there was no statistically signif-
icant difference between both groups even in the ++ and
+++ categories (Table 3).
As regards the correlation between the level of circulating
serum autoantibodies and other disease variables in the study
COPD patients such as age, BMI, spirometric data, arterial
blood gases parameters and 6MWD, it was found that there
was no statistically signiﬁcant correlation (Fig. 5).
Discussion
COPD is a major public health problem because: (1) it causes
signiﬁcant morbidity and mortality which is expected to
increase worldwide in the near future; (2) it imposes an
enormous global healthcare cost. However, because the
pathogenesis of COPD is poorly understood, treatment is
mostly symptomatic and new therapeutic strategies are limited
[16,17].
The present study tried to investigate the unexplored role of
the immune system in the pathogenesis of COPD and its rela-
tionship with age, body mass index, spirometric and blood
Table 1 Statistical comparison between COPD cases and control group in the arterial blood gas parameters.
ABG parameters Cases
(n= 31)
Mean ± S.D.
Control group
(n= 12)
Mean ± S.D.
P-value Statistical signiﬁcance
PaO2 (mmHg) 72.42 ± 14.62 86.92 ± 4.21 0.002
* Sig.
PaCO2 (mmHg) 42.23 ± 7.56 39.67 ± 0.78 0.252 N.S
SO2 % 93.23 ± 3.63 97.00 ± 1.21 0.001
* Sig.
* P-Value <0.05 means statistically signiﬁcant.
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Figure 3 Statistical comparison between COPD cases and
control group in 6 min walk distance (6MWD).
Table 2 Statistical comparison between COPD cases and control group according to the level of serum circulating auto-antibodies.
Autoantibodies Cases
(n= 31)
Control group
(n= 12)
Total
(n= 43)
P-Value Statistical signiﬁcance
No. % within group No. % within group No. % within group
ANA ve 29 93.5 12 100 41 95.3 1.000 N.S
+ve 2 6.5 0 0 2 4.7
ASMA ve 11 35.5 5 41.7 16 37.2 0.737 N.S
+ve 20 64.5 7 58.3 27 68.2
AMA ve 29 93.5 12 100 41 95.3 1.000 N.S
+ve 2 6.5 0 0 2 4.7
APA ve 31 100 11 91.7 42 97.7 0.279 N.S
+ve 0 0 1 8.3 1 2.3
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Figure 4 Statistical comparison between COPD cases and
control group according to the level of serum circulating auto-
antibodies.
Table 3 Statistical comparison between COPD cases and control group according to the grade of positivity of ASMA.
ASMA grade Cases Control group Total
ve No. 11 5 16
% within group 35.5% 41.7% 37.2%
+ No. 15 5 20
% within group 48.4% 41.7% 46.5%
++ No. 5 1 6
% within group 16.1% 8.3% 14%
+++ No. 0 1 1
% within group 0% 8.3% 2.3%
Total No. 31 12 43
% within group 100% 100% 100%
P-value = 0.372
Statistical signiﬁcance N.S.
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Figure 5 Correlation between autoantibodies and Age, BMI,
Spirometric data, ABG parameters and 6MWD.
Role of autoimmunity in the pathogenesis of COPD 359gases parameters. If true, this hypothesis will generate new
therapeutic opportunities in COPD.
In The present study the prevalence of positive circulating
autoantibodies in clinically stable COPD patients was found
not signiﬁcant when compared with healthy non smoker con-
trol group. Also there was no statistically signiﬁcant correla-
tion between the presence of autoantibodies and the different
variables measured in the group of COPD patients such as
age, BMI, 6MWD, spirometric and arterial blood gases
parameters.
The present study agreed with Cottin et al. [18], who found
no evidence for anti-elastin autoantibody response in patients
with combined pulmonary ﬁbrosis and emphysema.
Additionally this study agreed with Greene et al. [19], who
investigated the presence of autoantibodies against elastin and
collagen derived proline–glycine–proline in patients with
COPD and a1-antitrypsin deﬁciency and did not observe in-
creased autoantibody levels.
Also Brandsma et al. [20], did not ﬁnd an increased pres-
ence of autoantibodies against elastin, collagen and decorin
in COPD when compared two separate groups of COPD pa-
tients and healthy control subjects. However they observed a
signiﬁcant higher level of anti-decorin IgG autoantibodies in
COPD ex-smoker than COPD current smokers in one of the
two groups.
On the other hand the present study disagreed with Agusti
et al. [21] who found that COPD shares many clinical and
pathophysiological characteristics of several autoimmune dis-
eases such as rheumatoid arthritis (RA). They explained this
by: (1) Smoking is a risk factor for both COPD [22] and RA
[23]; (2) Once initiated, the inﬂammatory response of RA is
self-perpetuating [24]. To some extent, this may be analogous
to the continued airway inﬂammation seen after cessation of
smoking [25]; (3) exacerbations occur both in RA and COPD.
Yet, while in COPD exacerbations are precipitated by external
factors such as airway infection and air pollution [26], in RA
they are considered an integral part of the disease process,
characterized by T cells sensitized to either cartilage epitopes
[27] and/or degradation products of intestinal bacteria that mi-
mic them [24] homing to the synovium and contributing to the
maintenance or ampliﬁcation of the inﬂammatory process; (4)
Finally, similarities between the inﬂammatory cells (neutro-
phils, macrophages, T lymphocytes) and cytokines (tumor
necrosis factor (TNF)-a, interleukin (IL)-6, IL-8) involved in
the pathogenesis of RA [28] and COPD [6] are remarkable.Hemminki et al. [29], reported an increased prevalence of
COPD in patients with autoimmune disease and suggested that
the presence of autoimmunity is a risk factor for the develop-
ment of COPD. Also Birring et al. [30], previously reported an
increased prevalence of autoimmune diseases in patients with
COPD who have never smoked and they found that these pa-
tients tended to be elderly females and many had a blood lym-
phopenia, positive autoantibodies and airway inﬂammation.
The present study also disagreed with Birring et al. [31] and
Raj et al. [32] who found a four-fold increase in the prevalence
of COPD in patients with autoimmune bowel disease.
Also Tzouvelekis et al. [33] investigated the immunologic
proﬁle of a relatively large cohort of patients with CPFE and
compared it to that of observed in patients with IPF without
emphysema, using a complete panel of clinical, serum and his-
topathologic markers. They found the following: (1) Increased
number of CPFE patients with positive ANA proﬁle compared
to patients with IPF without emphysema; (2) Increased num-
ber of CPFE patients with elevated serum p-ANCA titers com-
pared to none with IPF without emphysema; (3) Massive
inﬁltration of clusters of CD20+ cells forming lymphoid folli-
cles immediately adjacent to areas of ﬁbroblastic foci in lung
biopsy samples from CPFE patients with positive serum
immunologic proﬁle (ANCA and/or ANA) compared to pa-
tients with negative proﬁle, suggesting the presence of antibody
producing B cells within the injured lung.
Nu´n˜ez and colleagues [34] suggested that an autoimmune
component might play a signiﬁcant role in the pathogenic
mechanism of COPD. Also Nu´n˜ez and colleagues [34] were
targeted to ﬁnd out if ANA and AT can either be nonspeciﬁc
markers of an ongoing autoimmune response [35] or alterna-
tively, they may be directly involved in the pathogenesis of
the disease. They found that ANA titers were not related to
lung function, current smoking or comorbidity and that the
most frequent antigen speciﬁcities of ANA in other autoim-
mune diseases (ENA, dsDNA) were negative, supporting the
possibility that autoantibodies are nonspeciﬁc markers of
ongoing autoimmune response [36]. By contrast, they found
that more than 90% of AT positive patients were SMA posi-
tive and AT were inversely related to airﬂow limitation and
DLCO impairment supporting the possibility that autoanti-
bodies may be directly involved in the pathogenesis of the
disease.
The present study concluded that autoimmunity itself does
not play a signiﬁcant role in the pathogenic mechanisms of
COPD and that the presence of autoantibodies is not related
to the pulmonary components of the disease. Further are stud-
ies needed to be carried out on a larger number of COPD pa-
tients to ﬁnd out the incidence of autoimmune diseases in
COPD, although systemic inﬂammation associated with
COPD could result in several systemic manifestations, such
as cardiovascular diseases and metabolic abnormalities Fur-
ther studies are needed to ﬁnd out other factors than smoking
for the development of COPD since most smokers do not de-
velop COPD aiming for the development of novel diagnostic,
prognostic, and/or treatment approaches for this otherwise
medically refractory disease.
There may be some limitations and explanations for the
ﬁndings in the present study: (1) Sex distribution in the study
population; the present study included only males, while previ-
ous studies which suggested a possible association between
autoimmunity and COPD such as this performed by Lee
360 M.M. Shaban et al.et al. [37] included male and females with higher percentage of
females. (2) Smoking history in the study population; the
COPD patients included in this study were only current smok-
ers while some previous studies such as this performed by
Brandsma et al. [20] included current, ex-smokers and non
smokers and they found a higher level of anti-decorin IgG
autoantibodies in COPD ex-smoker compared to COPD cur-
rent smokers. This was also consistent with the study of Lee
et al. [37] in which the majority of COPD patients were ex-
smokers. (3) Finally, it is likely that the autoantibody response
in COPD can be directed against many different antigens,
which may vary between individuals. Such variability will
make it more difﬁcult to detect the presence of autoantibodies
against a speciﬁc antigen in any given group. So investigation
of the autoantibody response in COPD should be focused on
the presence of speciﬁc antibody responses directed against
lung tissue components, as Feghali-Bostwick et al. [38] did,
when they showed the presence of autoantibodies against lung
epithelial cells and also they found the deposition of IgG com-
plexes in the lung.Conﬂict of interest
There is no conﬂict of interest.References
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